We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi's mRNA Vaccine for Coronavirus to Enter Clinical Stage
Read MoreHide Full Article
Sanofi’s (SNY - Free Report) global vaccines business unit Sanofi Pasteur and Translate Bio, Inc. (TBIO - Free Report) announced promising pre-clinical data on their coronavirus vaccine candidate MRT5500. Pre-clinical data demonstrated a favorable immune response profile against SARS-CoV-2 in mice and non-human primates.
The preclinical data showed that two doses of MRT5500 induced neutralizing antibody levels significantly higher than those observed in COVID-19 patients.
The companies evaluated four dose levels — 0.2, 1, 5 and 10 µg per dose — of MRT5500 in mice and three dose levels — 15, 45 and 135 µg per dose — in non-human primates (NHPs). The vaccine has been developed as a two-administration vaccination schedule, three weeks apart.
Pre-clinical findings from the mice study showed that the candidate induced higher levels of binding antibodies and neutralizing antibodies specific to the SARS-CoV-2 spike protein with higher level of dose. First administration of MRT5500 achieved 100% seroconversion at all dose levels and a further increase in titers was observed following a second administration in the mice.
MRT5500 induced significantly higher levels of neutralizing antibody titers in NHPs compared to human convalescent sera by day 35. The candidate exhibited a Th1-biased T cell response against SARS-CoV-2 in both mice and NHPs.
These outcomes supported selection of the candidate for clinical development. A phase I/II study is planned for late 2020 to evaluate MRT550 in humans. Please note that Sanofi and Translate Bio have a collaboration agreement to develop novel mRNA vaccines, aimed at broadly addressing all current and future infectious diseases including COVID-19.
Shares of Sanofi have dipped 0.5% so far this year compared with the industry’s decrease of 0.9%.
Apart from MRT5500, Sanofi is developing another COVID-19 vaccine candidate in collaboration with Glaxo (GSK - Free Report) . Sanofi’s recombinant protein-based technology is being combined with Glaxo’s pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine. In September, a phase I/II study was initiated to evaluate their adjuvanted vaccine. Initial results from the study are expected in early December 2020. If phase I/II study data is favorable, the companies are likely to begin a pivotal phase III study before the end of this year.
Meanwhile, we note that there are other players in the coronavirus vaccine field with a few already in late-stage development. Leading coronavirus vaccine developers include Moderna (MRNA - Free Report) , Pfizer/BioNTech, AstraZeneca/Oxford University and J&J. Currently, Pfizer/BioNTech’s mRNA-based coronavirus vaccine candidate is leading the race with initial data from a late-stage study expected by the end of this month. Positive outcomes will likely support an emergency use authorization from the FDA.
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
Sanofi's mRNA Vaccine for Coronavirus to Enter Clinical Stage
Sanofi’s (SNY - Free Report) global vaccines business unit Sanofi Pasteur and Translate Bio, Inc. (TBIO - Free Report) announced promising pre-clinical data on their coronavirus vaccine candidate MRT5500. Pre-clinical data demonstrated a favorable immune response profile against SARS-CoV-2 in mice and non-human primates.
The preclinical data showed that two doses of MRT5500 induced neutralizing antibody levels significantly higher than those observed in COVID-19 patients.
The companies evaluated four dose levels — 0.2, 1, 5 and 10 µg per dose — of MRT5500 in mice and three dose levels — 15, 45 and 135 µg per dose — in non-human primates (NHPs). The vaccine has been developed as a two-administration vaccination schedule, three weeks apart.
Pre-clinical findings from the mice study showed that the candidate induced higher levels of binding antibodies and neutralizing antibodies specific to the SARS-CoV-2 spike protein with higher level of dose. First administration of MRT5500 achieved 100% seroconversion at all dose levels and a further increase in titers was observed following a second administration in the mice.
MRT5500 induced significantly higher levels of neutralizing antibody titers in NHPs compared to human convalescent sera by day 35. The candidate exhibited a Th1-biased T cell response against SARS-CoV-2 in both mice and NHPs.
These outcomes supported selection of the candidate for clinical development. A phase I/II study is planned for late 2020 to evaluate MRT550 in humans. Please note that Sanofi and Translate Bio have a collaboration agreement to develop novel mRNA vaccines, aimed at broadly addressing all current and future infectious diseases including COVID-19.
Shares of Sanofi have dipped 0.5% so far this year compared with the industry’s decrease of 0.9%.
Apart from MRT5500, Sanofi is developing another COVID-19 vaccine candidate in collaboration with Glaxo (GSK - Free Report) . Sanofi’s recombinant protein-based technology is being combined with Glaxo’s pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine. In September, a phase I/II study was initiated to evaluate their adjuvanted vaccine. Initial results from the study are expected in early December 2020. If phase I/II study data is favorable, the companies are likely to begin a pivotal phase III study before the end of this year.
Meanwhile, we note that there are other players in the coronavirus vaccine field with a few already in late-stage development. Leading coronavirus vaccine developers include Moderna (MRNA - Free Report) , Pfizer/BioNTech, AstraZeneca/Oxford University and J&J. Currently, Pfizer/BioNTech’s mRNA-based coronavirus vaccine candidate is leading the race with initial data from a late-stage study expected by the end of this month. Positive outcomes will likely support an emergency use authorization from the FDA.
Sanofi Price
Sanofi price | Sanofi Quote
Zacks Rank
Sanofi currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>